MétaCan
Menu
← Back to cohort

Abstract 14065: Effectiveness and Tolerability of Perindopril 3.5 Mg/amlodipine 2.5 Mg Single Pill Combination in Newly Diagnosed Patients With Hypertension. The Simple National Study Across Canada

2020· article· en· W3098785440 on OpenAlexaffabout
Stella S. Daskalopoulou, Romualda Villatte

Bibliographic record

VenueCirculation · 2020
Typearticle
Languageen
FieldMedicine
TopicBlood Pressure and Hypertension Studies
Canadian institutionsMcGill University
Fundersnot available
KeywordsMedicineTolerabilityPerindoprilAmlodipineBlood pressureCalcium channel blockerInternal medicinePillDiastoleUrologyPharmacologyAdverse effect

Abstract

fetched live from OpenAlex

Introduction: The perindopril 3.5 mg /amlodipine 2.5 mg is the only available angiotensin converting enzyme inhibitor and a calcium channel blocker single pill combination (SPC) with market approval as a first-line therapy indication for hypertension. Hypothesis: Effectiveness, tolerability of, and the compliance to this SPC in patients with newly diagnosed hypertension. Methods: National, prospective, open-label, non-interventional study. Patients (n=1179) were initially prescribed the lowest dose SPC perindopril 3.5 mg/amlodipine 2.5 mg with possible up-titration after 4-weeks treatment (to 7/5 mg up to 14/10 mg). Office blood pressure (BP) at baseline, 3 months (M3), 6 months (M6), and the percentage of patients with normalized BP were assessed. Data were stratified by age, systolic BP category at baseline, and diabetic status. Results: Significant early systolic/diastolic BP decreases from baseline (mean±SD) were observed since the first visit: -20.8±14.7/-11.7±9.2 (P<0.001) at M3 and was slightly greater at M6: -22.9±14.5/-13.4±9.1, (P< 0.001), suggesting that the majority of the effect was obtained within the first 3 months; 82% of patients continued at the same dose, 17.5% were up-titrated. BP target was achieved in 61.4% of patients at M3, in 70.2% at M6. Significant BP decreases were observed in all age subgroups, in diabetic and non-diabetic patients. At both visits, significantly higher efficacy was observed in patients with stage 2 hypertension ( -27.0±15.3/-13.2±9.6, at M3 and -29.6±15.4/-15.0±9.2, at M6; p<0.002 for all) than stage 1. The greatest efficacy was observed in non-diabetic patients with stage 2 hypertension at M6 (-35.0±12.5/-17.2±8.9; P<0.001). Good compliance was reported in 95% of patients. During the study, emergent adverse events were reported in 95 (7.2%) patients, with no severe safety concerns raised; the intensity was mostly mild (76.8%) or moderate (21.1%) Conclusions: The Canadian SIMPLE study confirms the early benefits, tolerability of and compliance to the SPC perindopril/amlodipine 3.5 mg/2.5 mg, with a possibility of up-titration. This supports the guidelines recommendation for SPC use in newly diagnosed patients with hypertension as a first-line therapeutic option in clinical practice.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.451
Threshold uncertainty score0.908

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.253
Teacher spread0.223 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2020
Admission routes2
Has abstractyes

Explore more

Same venueCirculation→Same topicBlood Pressure and Hypertension Studies→French-language works237,207→